Organon’s VTAMA Earns Strong Pediatric AD Recommendation in AAD Guidelines
Event summary
- VTAMA cream received a strong recommendation in the 2026 AAD pediatric atopic dermatitis guidelines, the first of their kind.
- It is the only steroid-free topical treatment with high certainty of evidence across all severities for children aged 2+.
- The FDA approved VTAMA for AD in adults and pediatrics in December 2024, following its initial approval for plaque psoriasis in 2022.
The big picture
The AAD’s strong recommendation positions VTAMA as a key player in pediatric atopic dermatitis treatment, an underserved market with distinct safety and dosing considerations. Organon’s focus on steroid-free options aligns with growing preference for non-steroidal therapies in dermatology. The approval expands VTAMA’s addressable patient population beyond adults with psoriasis.
What we're watching
- Market Differentiation
- Whether VTAMA’s steroid-free profile and broad pediatric indication will drive market share gains against competitors.
- Clinical Adoption
- The pace at which dermatologists incorporate VTAMA into treatment plans for pediatric AD patients.
- Regulatory Expansion
- Potential approvals in other regions or for additional indications beyond AD and psoriasis.
Related topics